Enhancing T cell responses to early-stage tumors
Co-stimulation of T cell responses to nascent, emerging tumors
['FUNDING_R21'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-11114661
This study is looking at how to boost the immune system, especially T cells, to help them spot and fight early-stage tumors before they turn into cancer, and it's for anyone interested in improving cancer prevention.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-11114661 on ClinicalTrials.gov |
What this research studies
This research investigates how the immune system, particularly T cells, can be better activated to recognize and eliminate early-stage tumors before they develop into full-blown cancers. The approach focuses on understanding the mechanisms by which tumor-derived signals can prime T cell responses, utilizing a specific pathway involving heat shock proteins and their interaction with immune cells. By studying these interactions in both mice and humans, the research aims to identify ways to enhance the body's natural defenses against cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a heightened risk of developing cancer, particularly those with known deficiencies in T cell function.
Not a fit: Patients with advanced-stage cancers or those who do not have any known immune deficiencies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for cancer prevention by improving the immune system's ability to detect and destroy nascent tumors.
How similar studies have performed: Previous research has shown promising results in enhancing immune responses to tumors using similar immunological approaches, indicating potential for success in this area.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BINDER, ROBERT J — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: BINDER, ROBERT J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: cancer antigens, cancer evasion, cancer immune escape, cancer immune evasion, cancer immunology